bpc-157 human clinical trials safety review Preclinical evaluation of body protective compound-157, a potential drug for treating various wounds bpc-157 human clinical trials evidence

(NOTE: There is an ongoing debate about whether 5-Amino 1MQ should be classified as a small molecule or a peptide, but thats a discussion far beyond the scope of this article) It was discovered in 2017 by researchers at the University of Texas who were attempting to discover small, selective, and membrane-permeable inhibitors of an enzyme called nicotinamide N -methyltransferase (NNMT)

Researchers have described this as the compounds key differentiating feature in systematic reviews of the preclinical literature

Differences in peptide purity, identity, or manufacturing consistency can affect experimental reproducibility

Other companies view NAD+ as just an add on and dont necessarily try and compete on price and bring new customers in through NAD+

(PubMed) Watkins D, Rosenblatt DS

In this guide, well break down: What current research says about BPC-157 safety Reported side effects and potential adverse reactions Long-term safety concerns How to reduce your risk when using peptides What Is BPC-157 and How Does It Work